Medical Crossfire®: Menin Inhibitors in AML—Dissecting the Data to Define the Role

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Naval Daver, MD; Courtney DiNardo, MD; and Eunice Wang, MD; discuss the rationale for treatment with menin inhibitors—and the data showing their efficacy and safety—in acute myeloid leukemia (AML).

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Determine the mechanistic rationale supporting the role of menin inhibitors in AML treatment
• Discuss the potential implications of recent trial evidence and emerging monotherapy/combination therapy trials evaluating menin inhibitors in patients with AML
• Develop individualized care plans for patients with NPM1-mutated and/or KMT2A-rearranged AML based on clinical trial evidence
• Devise strategies to proactively monitor and mitigate treatment-related toxicities and/or treatment resistance in patients with AML receiving menin inhibitors

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Janssen Scientific Affairs, LLC, Kura Oncology, and Syndax Pharmaceuticals, Inc.

Chair:

Naval Daver, MD

Professor of Medicine
The University of Texas MD Anderson Cancer Center
Director- Leukemia Research Alliance Program
Houston, TX

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Agios, Amgen, Arog, Astellas, Bristol -Myers Squibb, Celgene, DaiichiSankyo, Genentech, Gilead, ImmunoGen, Jazz, KITE, Novartis, Pfizer, Servier, Shattuck Labs, Stemline/Menarini, Syndax, Trillium; Grant/Research Funding (to institution): AbbVie, Amgen, Astellas, Bristol-Meyers Squibb, Daiichi-Sankyo, FATE Therapeutics, Genentech, Gilead, Glycomimetics, Hanmi, ImmunoGen, KITE, Novimmune, Pfizer, Servier, Trillium, rovagene.

Faculty:

Courtney DiNardo, MD

Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Advisor, Consultant, Fee for Service Recipient: Abbvie, Astellas, AstraZeneca, BMS, Daiichi-Sankyo, GenMab, GSK, Rigel, Servier, Schrodinger; Grant/Research Funding: Abbvie, Astex, Auron, BMS, Remix, Rigel, Schrodinger, Servier

Eunice Wang, MD

Chief, Leukemia Service
Medical Director, Chemotherapy/Infusion Center
Roswell Park Comprehensive Cancer Center
Buffalo, NY

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Abbvie, Blueprint, Daiichi Sankyo/UCB Japan, Johnson & Johnson/Janssen, Kite/ Gilead, Kura Oncology, Novartis, Qiagen, Rigel, Ryvu Therapeutics, Schrodinger, SERVIER, Stemline Therapeutics, Takeda, Syndax; Speakers’ Bureau: Astellas, Daiichi Sankyo/UCB Japan, Pfizer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information about using genomics to improve AML therapy, managing toxicities associated with menin inhibitors, and data for menin inhibitor-based combination therapies, go to https://www.gotoper.com/courses/medical-crossfire-menin-inhibitors-in-amldissecting-the-data-to-define-the-role-3ng9.

Release Date

March 17, 2026

Expiration Date

March 17, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.